GC Biopharma and Thai Red Cross Forge Alliance on Plasma Therapies

GC Biopharma has entered into a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to enhance collaboration in the field of plasma-derived therapies. The agreement, signed on August 14, 2025, aims to bolster Thailand’s capabilities in plasma fractionation through training and technology transfer initiatives.

This new agreement builds on a collaborative relationship that began in 2015, when GC Biopharma aided in establishing Thailand’s plasma fractionation facility. Under the terms of the MOU, both parties will work together to develop training and exchange programs that focus on transferring advanced manufacturing technologies. This initiative is designed to strengthen local production capabilities for plasma-derived medicinal products.

Goals and Impacts of the Partnership

Vice President of GC Biopharma, Hyoungjun Park, emphasized the significance of the MOU, stating, “This MOU is a vital step in expanding advanced technology across Asia while contributing to public welfare.” The partnership is expected to enhance workforce development, improve product quality and safety, and contribute to overall public health security in Thailand and the surrounding region.

The Director of the National Blood Centre at TRCS, Assoc. Prof. Dootchai Chaiwanichsiri, highlighted the collaborative nature of this agreement, noting its importance for human resource development and technology transfer. The training programs are expected to facilitate the growth of a skilled workforce equipped to navigate the complexities of plasma-derived therapies.

Strategic Expansion in Southeast Asia

GC Biopharma’s agreement with TRCS reflects its broader strategy to expand its plasma-derived therapeutics business. The company made its entry into the U.S. immunoglobulin market in 2024 and is actively pursuing partnerships in Southeast Asia, where domestic plasma fractionation capacities are evolving.

This partnership not only signifies a commitment to advancing healthcare in Thailand but also positions GC Biopharma as a key player in the region’s burgeoning plasma-derived therapies market. With a focus on quality and safety, the collaboration is poised to have a lasting impact on public health initiatives.

As the landscape for plasma-derived therapies continues to evolve, the strengthening of such partnerships will be crucial in addressing healthcare needs in Thailand and beyond.